tradingkey.logo
๎™
๎™ผ
tradingkey.logo
๎™

60 Degrees Pharmaceuticals Inc

SXTP
1.556USD
+0.066+4.46%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
144.47K์‹œ๊ฐ€์ด์•ก
1.38P/E TTM
๎™

60 Degrees Pharmaceuticals Inc

1.556
+0.066+4.46%

์ž์„ธํ•œ ๋‚ด์šฉ์€ 60 Degrees Pharmaceuticals Inc ํšŒ์‚ฌ

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Companyโ€™s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

60 Degrees Pharmaceuticals Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ SXTP
ํšŒ์‚ฌ ์ด๋ฆ„60 Degrees Pharmaceuticals Inc
์ƒ์žฅ์ผJul 12, 2023
CEODow (Geoffrey S)
์ง์› ์ˆ˜3
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒJul 12
์ฃผ์†Œ1025 Connecticut Avenue Nw
๋„์‹œWASHINGTON
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ20036
์ „ํ™”12023275422
์›น์‚ฌ์ดํŠธhttps://60degreespharma.com/
์ข…๋ชฉ ์ฝ”๋“œ SXTP
์ƒ์žฅ์ผJul 12, 2023
CEODow (Geoffrey S)

60 Degrees Pharmaceuticals Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+49.83%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+44.26%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
59.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.36K
+49.83%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
+44.26%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Feb 15
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sun, Feb 15
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
Jane Street Capital, L.L.C.
0.43%
Xu (Cheryl)
0.31%
๊ธฐํƒ€
94.50%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Orca Capital GmbH
3.23%
Dow (Geoffrey S)
0.88%
Knight Therapeutics, Inc.
0.66%
Jane Street Capital, L.L.C.
0.43%
Xu (Cheryl)
0.31%
๊ธฐํƒ€
94.50%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
3.26%
Individual Investor
1.39%
Corporation
0.66%
Research Firm
0.43%
Investment Advisor/Hedge Fund
0.24%
Hedge Fund
0.13%
Bank and Trust
0.03%
๊ธฐํƒ€
93.86%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Jan 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Thu, Jan 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
25
52.23K
4.06%
-28.54K
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Orca Capital GmbH
166.23K
3.93%
+166.23K
--
Jul 16, 2025
Dow (Geoffrey S)
45.42K
1.07%
+22.63K
+99.30%
Dec 15, 2025
Knight Therapeutics, Inc.
33.90K
0.8%
+14.67K
+76.26%
Sep 30, 2024
Xu (Cheryl)
15.82K
0.37%
+7.00K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
12.45K
0.29%
-67.00
-0.54%
Sep 30, 2025
Tower Research Capital LLC
3.14K
0.07%
+542.00
+20.86%
Sep 30, 2025
Miller (Tyrone)
5.27K
0.12%
--
--
Aug 26, 2025
Landon (Kristen)
4.54K
0.11%
--
--
Aug 26, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
Jan 15, 2026
Merger
4โ†’1
Feb 20, 2025
Merger
5โ†’1
Feb 20, 2025
Merger
5โ†’1
Feb 20, 2025
Merger
5โ†’1
Feb 20, 2025
Merger
5โ†’1
Aug 06, 2024
Merger
12โ†’1
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
Jan 15, 2026
Merger
4โ†’1
Feb 20, 2025
Merger
5โ†’1
Feb 20, 2025
Merger
5โ†’1
Feb 20, 2025
Merger
5โ†’1
Feb 20, 2025
Merger
5โ†’1
Aug 06, 2024
Merger
12โ†’1
Aug 06, 2024
Merger
12โ†’1
Aug 06, 2024
Merger
12โ†’1
Aug 06, 2024
Merger
12โ†’1
KeyAI
๎™